Rozanolixizumab effectively reduces gMG symptoms, especially ocular, with significant score improvements in MG-ADL, QMG, and MGII compared to placebo. The drug is well-tolerated, with primarily mild ...

Heightened focus on delays in diagnosing generalized myasthenia gravis (gMG) follows the promise of better results for some patients with newer treatments that include complement inhibitors and ...

Zilucoplan demonstrates sustained efficacy in gMG, enabling rapid functional improvement and corticosteroid tapering, potentially altering disease management. Early responders maintained high response ...

A phase 3 study of AstraZeneca’s gefurulimab has hit its primary and all secondary endpoints, teeing up talks with regulators about the potential blockbuster generalized myasthenia gravis (gMG) ...

While Johnson & Johnson isn't the first to secure FDA approval for an FcRn-blocking antibody in myasthenia gravis, the New Jersey drugmaker is confident that a broad label will land its product an ...

Seeking to build out its pipeline-in-a-product Vyvgart, Argenx is returning to its roots with plans to pursue an expanded approval in the drug’s initial myasthenia gravis indication. On Monday, Argenx ...

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced ...

Regeneron has reported a phase 3 win in generalized myasthenia gravis (gMG), positioning the pharma to file for FDA approval of its siRNA candidate in the increasingly competitive neuromuscular ...